Table 1.
Baseline characteristics.
| Baseline characteristics | % (n = 107) |
|---|---|
| Men | 25.2 (27/107) |
| Women | 74.8 (80/107) |
| Average age at the start of therapy in years (range) | 46 (20–76) |
| Ethnicity | |
| Caucasian | 85.0 (91/107) |
| African American | 11.2 (12/107) |
| Hispanic | 0.9 (1/107) |
| Not reported/other | 2.8 (3/107) |
| Duration of rituximab treatment (months)a | 33.2 ± 24.43 |
| Multiple sclerosis diagnosis | |
| Relapsing–remitting | 50.5 (54/107) |
| Secondary progressive | 34.5 (37/107) |
| Primary relapsing | 5.6 (6/107) |
| Primary progressive | 4.7 (5/107) |
| Unclassified | 4.7 (5/107) |
| RRMS patients baseline characteristics (n = 54) | |
| Average age at the start of therapy in years (range) | 42.2 (19–71) |
| Duration of rituximab treatment (months)a | 32.9 ± 25.0 |
| EDSS score at baselinea | 2.9 ± 1.6 |
| EDSS score at the end of treatmenta | 2.5 ± 1.8 |
a
Data presented as average ± standard deviation.
RRMS: relapsing–remitting multiple sclerosis; EDSS: Expanded Disability Status Scale.